Literature DB >> 14565846

Prolactin stimulates cell proliferation through a long form of prolactin receptor and K+ channel activation.

Fabien Van Coppenolle1, Roman Skryma, Halima Ouadid-Ahidouch, Christian Slomianny, Morad Roudbaraki, Philippe Delcourt, Etienne Dewailly, Sandrine Humez, Alexandre Crépin, Isabelle Gourdou, Jean Djiane, Jean-Louis Bonnal, Brigitte Mauroy, Natalia Prevarskaya.   

Abstract

PRL (prolactin) has been implicated in the proliferation and differentiation of numerous tissues, including the prostate gland. However, the PRL-R (PRL receptor) signal transduction pathway, leading to the stimulation of cell proliferation, remains unclear and has yet to be mapped. The present study was undertaken to develop a clear understanding of the mechanisms involved in this pathway and, in particular, to determine the role of K(+) channels. We used androgen-sensitive prostate cancer (LNCaP) cells whose proliferation is known to be stimulated by PRL. Reverse transcriptase PCR analysis showed that LNCaP cells express a long form of PRL-R, but do not produce its intermediate isoform. Patch-clamp techniques showed that the application of 5 nM PRL increased both the macroscopic K(+) current amplitude and the single K(+)-channel open probability. This single-channel activity increase was reduced by the tyrosine kinase inhibitors genistein, herbimycin A and lavandustine A, thereby indicating that tyrosine kinase phosphorylation is required in PRL-induced K(+) channel stimulation. PRL enhances p59( fyn ) phosphorylation by a factor of 2 after a 10 min application in culture. In addition, where an antip59( fyn ) antibody is present in the patch pipette, PRL no longer increases K(+) current amplitude. Furthermore, the PRL-stimulated proliferation is inhibited by the K(+) channel inhibitors alpha-dendrotoxin and tetraethylammonium. Thus, as K(+) channels are known to be involved in LNCaP cell proliferation, we suggest that K(+) channel modulation by PRL, via p59( fyn ) pathway, is the primary ionic event in PRL signal transduction, triggering cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14565846      PMCID: PMC1223902          DOI: 10.1042/BJ20030859

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  64 in total

1.  Verapamil inhibits proliferation of LNCaP human prostate cancer cells influencing K+ channel gating.

Authors:  V Rybalchenko; N Prevarskaya; F Van Coppenolle; G Legrand; L Lemonnier; X Le Bourhis; R Skryma
Journal:  Mol Pharmacol       Date:  2001-06       Impact factor: 4.436

2.  KV1.1 K(+) channels identification in human breast carcinoma cells: involvement in cell proliferation.

Authors:  H Ouadid-Ahidouch; F Chaussade; M Roudbaraki; C Slomianny; E Dewailly; P Delcourt; N Prevarskaya
Journal:  Biochem Biophys Res Commun       Date:  2000-11-19       Impact factor: 3.575

3.  Growth-promoting actions of prolactin, the hormone of lactation.

Authors:  Vincent Goffin; Paul A Kelly
Journal:  J Pediatr Endocrinol Metab       Date:  2002-06       Impact factor: 1.634

4.  Bcl-2-dependent modulation of Ca(2+) homeostasis and store-operated channels in prostate cancer cells.

Authors:  Fabien Vanden Abeele; Roman Skryma; Yaroslav Shuba; Fabien Van Coppenolle; Christian Slomianny; Morad Roudbaraki; Brigitte Mauroy; Frank Wuytack; Natalia Prevarskaya
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

5.  NMDA channel regulation by channel-associated protein tyrosine kinase Src.

Authors:  X M Yu; R Askalan; G J Keil; M W Salter
Journal:  Science       Date:  1997-01-31       Impact factor: 47.728

6.  Functional characterization of the intermediate isoform of the human prolactin receptor.

Authors:  J B Kline; H Roehrs; C V Clevenger
Journal:  J Biol Chem       Date:  1999-12-10       Impact factor: 5.157

7.  Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: possible involvement of a h-ether.a-gogo K+ channel.

Authors:  H Ouadid-Ahidouch; X Le Bourhis; M Roudbaraki; R A Toillon; P Delcourt; N Prevarskaya
Journal:  Receptors Channels       Date:  2001

Review 8.  The prolactin/growth hormone receptor family: structure/function relationships.

Authors:  V Goffin; P A Kelly
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-01       Impact factor: 2.673

9.  Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence.

Authors:  F Van Coppenolle; C Slomianny; F Carpentier; X Le Bourhis; A Ahidouch; D Croix; G Legrand; E Dewailly; S Fournier; H Cousse; D Authie; J P Raynaud; J C Beauvillain; J P Dupouy; N Prevarskaya
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-01       Impact factor: 4.310

Review 10.  Potassium channels: molecular defects, diseases, and therapeutic opportunities.

Authors:  C C Shieh; M Coghlan; J P Sullivan; M Gopalakrishnan
Journal:  Pharmacol Rev       Date:  2000-12       Impact factor: 25.468

View more
  18 in total

1.  Intermediate Ca2+-sensitive K+ channels are necessary for prolactin-induced proliferation in breast cancer cells.

Authors:  Malika Faouzi; Valérie Chopin; Ahmed Ahidouch; Halima Ouadid-Ahidouch
Journal:  J Membr Biol       Date:  2010-02-23       Impact factor: 1.843

Review 2.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

3.  Fyn regulates adipogenesis by promoting PIKE-A/STAT5a interaction.

Authors:  Margaret Chui Ling Tse; Xia Liu; Seran Yang; Keqiang Ye; Chi Bun Chan
Journal:  Mol Cell Biol       Date:  2013-02-25       Impact factor: 4.272

4.  Effects of metoclopramide on mRNA levels of steroid 5α-reductase isozymes in prostate of adult rats.

Authors:  Pilar Sánchez; Jesús M Torres; Beatriz Castro; José F Frías; Esperanza Ortega
Journal:  J Physiol Biochem       Date:  2012-07-18       Impact factor: 4.158

Review 5.  Prolactin receptor in regulation of neuronal excitability and channels.

Authors:  Mayur J Patil; Michael A Henry; Armen N Akopian
Journal:  Channels (Austin)       Date:  2014       Impact factor: 2.581

6.  Prolactin stimulates prostate cell proliferation by increasing endoplasmic reticulum content due to SERCA 2b over-expression.

Authors:  Alexandre Crépin; Gabriel Bidaux; Fabien Vanden-Abeele; Etienne Dewailly; Vincent Goffin; Natalia Prevarskaya; Christian Slomianny
Journal:  Biochem J       Date:  2007-01-01       Impact factor: 3.857

7.  Prolactin induces a hyperpolarising current in rat paraventricular oxytocinergic neurones.

Authors:  A Sirzen-Zelenskaya; A E Gonzalez-Iglesias; J Boutet de Monvel; R Bertram; M E Freeman; U Gerber; M Egli
Journal:  J Neuroendocrinol       Date:  2011-10       Impact factor: 3.627

8.  Gene expression profile analysis of the spontaneous reversal of rat hepatic fibrosis by cDNA microarray.

Authors:  Qin Pan; Zhong-Bing Zhang; Xin Zhang; Jian Shi; Yue-Xiang Chen; Ze-Guang Han; Wei-Fen Xie
Journal:  Dig Dis Sci       Date:  2007-03-16       Impact factor: 3.199

9.  Comparative effects of prolactin versus ACTH, estradiol, progesterone, testosterone, and dihydrotestosterone on cortisol release and proliferation of the adrenocortical carcinoma cell line H295R.

Authors:  Sukanya Jaroenporn; Chie Furuta; Kentaro Nagaoka; Gen Watanabe; Kazuyoshi Taya
Journal:  Endocrine       Date:  2008-05-17       Impact factor: 3.633

10.  Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.

Authors:  Prasad Dandawate; Gaurav Kaushik; Chandrayee Ghosh; David Standing; Afreen Asif Ali Sayed; Sonali Choudhury; Dharmalingam Subramaniam; Ann Manzardo; Tuhina Banerjee; Santimukul Santra; Prabhu Ramamoorthy; Merlin Butler; Subhash B Padhye; Joaquina Baranda; Anup Kasi; Weijing Sun; Ossama Tawfik; Domenico Coppola; Mokenge Malafa; Shahid Umar; Michael J Soares; Subhrajit Saha; Scott J Weir; Animesh Dhar; Roy A Jensen; Sufi Mary Thomas; Shrikant Anant
Journal:  Gastroenterology       Date:  2019-11-29       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.